Repeated HBO Therapy in Myeloma Patients Undergoing High-Dose Therapy and Auto-HCT

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

April 22, 2022

Primary Completion Date

April 4, 2025

Study Completion Date

June 30, 2025

Conditions
Myeloma
Interventions
DRUG

Hyperbaric oxygen

The treatment consists of exposure to hyperbaric oxygen at 2.5 atmospheric absolutes (ATA) for a total of 90 minutes after compression to 2.5 atmosphere absolutes (ATA) in a monoplace hyperbaric chamber breathing 100% oxygen. The subjects will be in the chamber for a total of 120 minutes as approximately 10-15 minutes are spent during the compression and decompression phases and subjects have 5-10 minute room air breaks every 30 minutes of hyperbaric oxygen treatment.

Trial Locations (1)

14642-0001

James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Rochester

OTHER